Plain Compass 76 / services desk
Information tools for people considering ibogaine in Mexico, their families, and anyone trying to keep the care around the dose in view.
What this is
No sales pitch. No shortcuts.
Plain Compass 76 is an independent resource on safer ibogaine decision-making in Mexico. Our information services are built for the practical questions that can disappear when a treatment decision is reduced to a single substance or a single day.
The wider care-around-the-dose approach keeps attention on screening, monitoring, emergency readiness, follow-up, and uncertainty. This is not medical advice, and it cannot establish whether ibogaine is appropriate for any person.
Our approach and editorial principles explain why plain language, risk clarity, and evidence humility guide every guide, comparison, glossary entry, and FAQ collection.
Independent information resourceThe working pages
ISSUE 76 / MEXICO
Long-form guides organize the questions that sit before, during, and after an ibogaine decision: what screening may involve, what monitoring means in practice, how emergency planning is described, and what follow-up can reasonably be asked about.
Our frameworks separate marketing language from care questions. They are designed to help readers notice what is documented, what remains uncertain, and which concerns may warrant discussion with an appropriately qualified medical professional.
Comparison pages help families line up stated care processes without ranking providers or promising outcomes. For broader context, ibogaine detox center information can show how varied treatment descriptions and care claims may be.
Plain-language definitions and research summaries identify terms readers may encounter, including cardiac monitoring, contraindications, and follow-up. Ibogaine is an indole alkaloid with a complicated evidence and safety history, so careful wording matters.
Evidence, with the edges left visible
Research summaries distinguish between an observed finding, an early signal, and a conclusion that the available evidence cannot support. They do not turn limited studies into a promise of safety or benefit.
This caution matters because ibogaine has been associated with serious cardiac risk, including rhythm disturbances. The U.S. National Institute on Drug Abuse notes that ibogaine can have dangerous effects on the heart and may interact with other substances; its overview of ibogaine research and risks is a useful reference point for why screening and medical oversight questions are consequential.
Our material is intended to support informed choice, not replace individualized assessment. The point is to make uncertainty legible rather than hide it behind a confident answer.
The care-pathway lens
Frequently asked
These materials are information services for clearer discussion and comparison. They are not a substitute for medical, legal, or emergency guidance.
No. Plain Compass 76 is an independent information resource, not a clinic, medical provider, or licensed treatment center. The guides help readers form better questions about care systems and risk; they do not provide diagnoses, treatment plans, or medical clearance.
A dose is only one point in a wider safety picture. Screening, monitoring, emergency readiness, medication review, and follow-up are all part of the context people may need to examine. The material names these questions while being direct about the limits of current evidence.
No. A general guide cannot determine individual suitability or safety. People considering any substance with potentially serious effects should seek appropriately qualified, individualized medical guidance and use emergency services when an urgent situation arises.
Keep the whole picture in frame
Use Plain Compass 76 to orient your research around care systems, risk clarity, and the unanswered questions that deserve room in the decision.
See the dose & care pathway